Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis

Priyadarshana Ajithkumar,Sai Shyam Vasantharajan,Sharon Pattison,John L. McCall,Euan J. Rodger,Aniruddha Chatterjee

DOI: https://doi.org/10.3390/ijms25020874

IF: 5.6

2024-01-11

International Journal of Molecular Sciences

Abstract:Metastatic progression is a complex, multistep process and the leading cause of cancer mortality. There is growing evidence that emphasises the significance of epigenetic modification, specifically DNA methylation and histone modifications, in influencing colorectal (CRC) metastasis. Epigenetic modifications influence the expression of genes involved in various cellular processes, including the pathways associated with metastasis. These modifications could contribute to metastatic progression by enhancing oncogenes and silencing tumour suppressor genes. Moreover, specific epigenetic alterations enable cancer cells to acquire invasive and metastatic characteristics by altering cell adhesion, migration, and invasion-related pathways. Exploring the involvement of DNA methylation and histone modification is crucial for identifying biomarkers that impact cancer prediction for metastasis in CRC. This review provides a summary of the potential epigenetic biomarkers associated with metastasis in CRC, particularly DNA methylation and histone modifications, and examines the pathways associated with these biomarkers.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to identify potential epigenetic biomarkers related to colorectal cancer (CRC) metastasis, especially DNA methylation and histone modification. These epigenetic changes play an important role in the process of tumorigenesis and development, especially in terms of influencing gene expression and cell function. By exploring these epigenetic markers, the research aims to provide new methods for the early prediction of CRC metastasis, thereby improving the prognosis and treatment strategies of patients.

Specifically, the paper focuses on the following aspects:

1. **DNA methylation**: The research explores the role of DNA methylation in CRC metastasis, especially in lymph node, liver, lung and other distant metastases. For example, the paper discusses how the hypermethylation of certain tumor - suppressor genes (such as BMP2, CDKN2A, FAM134B) is associated with lymph node metastasis, and how the hypomethylation of the GCNT2 gene can be a potential biomarker for predicting lymph node metastasis.

2. **Histone modification**: The paper also explores the role of histone modification in CRC metastasis, including how these modifications affect gene expression and protein stability, thereby promoting the metastasis process.

3. **Early events**: The research points out that DNA methylation changes are an early event in CRC metastasis, and these changes have occurred before tumor cells progress to liver metastasis.

4. **Comprehensive analysis**: The paper uses a variety of techniques (such as methylation - specific PCR, microarray analysis, pyrosequencing, etc.) to identify and validate these epigenetic markers, and combines transcriptomics data for comprehensive analysis to better understand the impact of epigenetic changes on CRC metastasis.

In summary, the goal of this paper is to provide new biomarkers for the early diagnosis and prediction of CRC metastasis through in - depth research on epigenetic changes in CRC metastasis, thereby improving the treatment effect and survival rate of patients.